In more developed countries a very significant increased prevalence of autoimmune and allergic diseases was observed. At the same time, the prevalence of these diseases was lower in countries of high parasite endemicity.
Parasites ensure their very long survival in their infected hosts by releasing or inducing the production of several immunosuppressive or anti-inflammatory factors. They are often recognized as “masters of regulation”.
In the framework of the Immunoparasitology research performed during the last 20 years by groups at both Lille University and Pasteur Institute in Lille, a schistosome protein named P28GST has been characterized and produced as a recombinant molecule at GMP grade.
The cornerstone of Par’Immune is the development of P28GST as immunotherapeutic platform for autoimmune and inflammatory diseases such as Crohn’s disease, ulcerative colitis, or psoriasis.
Par’Immune aims to perform two Phase 2b clinical trials in order to reach the clinical proof of concept.
To proceed Par’Immune needed guidance of a specialized advising company in managing crucial tasks with regulatory implications such as protocol writing.
Par’Immune wanted the best. Boost4Health partners are in close contact with the service providers in their region and were able to introduce the best possible match: 4Clinics
4Clinics identified clear steps to proceed, bringing Par’Immune closer to the clinical trials. In fact the collaboration was so successful that Par’Immune is keen on working with 4Clinics again in the future.
